Pfizer, BioNTech Expand COVID-19 Vaccine Agreement with EU

By Tim Wright, Editor, Contract Pharma | 04.19.21

EU orders 100 million additional doses of COMIRNATY, bringing total doses to 600 million for 27 EU member states.

Pfizer Inc. and BioNTech SE have inked a deal to supply an additional 100 million doses of COMIRNATY, the companies’ COVID-19 vaccine, to the 27 European Union (EU) member states in 2021. This announcement is a result of the European Commission’s (EC) decision to exercise its option to purchase an additional 100 million doses under its expanded Advanced Purchase Agreement signed on February 17, 2021. This brings the total number of doses to be delivered to the EU to 600 million.
 
“We remain committed to moving as quickly and safely as possible to bring this vaccine to more people in Europe, as the deadly virus continues to wreak havoc across the continent,” said Albert Bourla, chairman and CEO, Pfizer. “To date, we have met all of our supply commitments to the EC and we plan to deliver 250 million doses to the European Union in Q2, a fourfold increase on Q1’s agreed quantity.”
 
Sean Marett, chief business and chief commercial officer, BioNTech, said, “The additional 100 million doses from this option exercise will further help to support the acceleration of the vaccination campaigns throughout the EU. We now intend to deliver a total of 600 million doses to the EU this year, which covers two thirds of the EU population and represents the largest cumulative supply agreement for COMIRNATY that we have agreed to date globally.”
 
COMIRNATY will be produced in BioNTech’s and Pfizer’s manufacturing sites in Europe.